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Abstract
Background: High density lipoprotein (HDL) has been proved to be a protective factor for coronary heart
disease. Notably, HDL in atherosclerotic plaques can be nitrated (NO2-oxHDL) and chlorinated (Cl-oxHDL) by
myeloperoxidase (MPO), likely compromising its cardiovascular protective effects.
Method: Here we determined the effects of NO2-oxHDL and Cl-oxHDL on SMC migration using wound
healing and transwell assays, proliferation using MTT and BrdU assays, and apoptosis using Annexin-V assay in
vitro, as well as on atherosclerotic plaque stability in vivo using a coratid artery collar implantation mice
model.
Results: Our results showed that native HDL promoted SMC proliferation and migration, whereas NO2-oxHDL
and Cl-oxHDL inhibited SMC migration and reduced capacity of stimulating SMC proliferation as well as
migration, respectively. OxHDL had no significant influence on SMC apoptosis. In addition, we found that
ERK1/2-phosphorylation was significantly lower when SMCs were incubated with NO2-oxHDL and Cl-oxHDL.
Furthermore, transwell experiments showed that differences between native HDL, NO2-oxHDL and Cl-oxHDL
was abolished after PD98059 (MAPK kinase inhibitor) treatment. In aortic SMCs from scavenger receptor BI
(SR-BI) deficient mice, differences between migration of native HDL, NO2-oxHDL and Cl-oxHDL treated SMCs
vanished, indicating SR-BI’s possible role in HDL-associated SMC migration. Importantly, NO2-oxHDL and
Cl-oxHDL induced neointima formation and reduced SMC positive staining cells in atherosclerotic plaque,
resulting in elevated vulnerable index of atherosclerotic plaque.
Conclusion: These findings implicate MPO-catalyzed oxidization of HDL may contribute to atherosclerotic
plaque instability by inhibiting SMC proliferation and migration through MAPK-ERK pathway which was
dependent on SR-BI.
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Background
High density lipoprotein (HDL) has been considered a
protective factor of coronary heart disease (CHD). How-
ever, recent clinical trials showed that HDL-elevating
medications failed to improve clinical outcomes in some
CHD patients [1, 2], suggesting that HDL’s function is
more important than its quality, which may be compro-
mised with certain modifications. HDL’s protective role
is also dependent on scavenger receptor BI (SR-BI), the
major receptor for HDL [3]. Myeloperoxidase (MPO)-
catalyzed oxidation, one of modifications for HDL,
which is closely linked to CHD [4, 5], could be further
classified into nitration (generating NO2-oxHDL) and
chlorination (generating Cl-oxHDL). Proteomic studies
have identified MPO as a component of advanced
human atherosclerotic lesions, and revealed that HDL,
more specifically, apolipoprotein A-I (apoA-I), the
primary protein constituent of HDL, is a selective target
for MPO-catalyzed nitration and chlorination in human
serum and atherosclerotic lesions [6, 7]. NO2-Tyr
(MPO-catalyzed nitration product) and Cl-Tyr (MPO-
catalyzed chlorination product) contents are dramatically
(6-fold higher than plasma) and selectively enriched
within apoA-I recovered from atherosclerotic lesions in
CHD patients [4, 8], oxidized apoA-I is in low abun-
dance within the circulation, but accounts for 20% of the
apoA-I in atherosclerotic plaque [9]. These results sug-
gest an important role of MPO-catalyzed HDL nitration
and chlorination in the pathogenesis of CHD.
Pathological studies showed that MPO expression was
significantly increased only when atherosclerosis pro-
gresses into atherosclerotic plaque [5], and reached its
highest level just before atherosclerotic plaque rupture
[10]. Therefore, MPO has been considered a marker of
unstable atherosclerotic plaque pathologically, angio-
graphically and clinically [11–14]. Clinical studies also
found that MPO serum levels could be used to pre-
dict the incidence of major adverse cardiac events
(MACE) in patients with acute coronary syndrome
(ACS) [15, 16]. These evidences identify MPO as a
marker for unstable advanced plaque. Recently, MPO
was found to form a complex with apoA-I and
oxidize apoA-I in human atherosclerotic plaque of
ACS patients [17], and serum concentrations of MPO
also correlated with HDL serum levels in ACS pa-
tients [18]. Moreover, apoA-I was also found over-
abundant in advanced plaques from unstable angina
pectoris patients and co-localized with MPO [19],
which raised an interesting question-whether MPO
weakens plaque stability in advanced atherosclerotic
lesions through oxidation of HDL. Pathological stud-
ies revealed significantly reduced vascular smooth
muscle cells (SMCs) in unstable atherosclerotic pla-
ques [20], and it is well known that plaque stability
in advanced atherosclerotic lesions is increased by
proliferation and migration of SMCs, but decreased
by SMC apoptosis [21–23]. It was previously reported
that HDL stimulates proliferation of SMCs [24, 25],
which may increase plaque stability and contribute to
HDL protection in CHD. Therefore, it is critical to
investigate whether MPO-oxidized HDL has any ad-
verse effects on SMCs, leading to plaque instability.
Thus in this article we asked how MPO-nitrated and
-chlorinated HDL modulates SMC migration, prolifer-




Fresh, fasting plasma was separated by centrifugation
from peripheral blood obtained from healthy subjects
as described previously (referred to as HDL) [26].
The study protocol was approved by the local ethics
committee. The clinical characteristics of plasma do-
nors were listed in Table 1. Briefly, HDL was isolated
from fresh plasma by ultracentrifugation (d = 1.063 to
1.21 g/mL), dialyzed against 3 × 1 L of endotoxin-free
phosphate-buffered saline (PBS) with 100 μM diethy-
lenetriamine pentaacetic acid (DTPA, Sigma, USA),
sterilized with 0.22 μm filter, and stored in sealed
tubes at 4 °C in dark until use within 1 month. The
concentrations of HDL used in the present study
were based on apoA-I content of HDL.
Animals
Three to six month old C57BL/6 background wild type
(WT) mice were used to isolate aortic vascular smooth
muscle cells. SR-BI (scavenger receptor BI) −/− mice
(C57BL/6 background) were obtained from Dr. George
Liu’s laboratory (Peking University, Beijing, China) [27].
Eight-week-old male ApoE−/− mice were purchsed
from Charles River Laboratories (Wilmington,
Massachusetts). Genotyping by PCR was performed
Table 1 Clinical characteristics of donors
Healthy donors average (n = 10)
Age, Year 24.2 ± 2.66
Sex, Male/Female 6/4
Triglyceride, mmol/L 1.06 ± 0.48
Total Cholesterol, mmol/L 4.20 ± 0.67
HDL-C, mmol/L 1.26 ± 0.28
LDL-C, mmol/L 2.26 ± 0.58
Data are presented as mean ± SD as indicated. HDL-C high density lipoprotein
cholesterol, LDL-C low density lipoprotein cholesterol, The donors were
generally healthy with no medical history of hyperlipidemia, cardiovascular
disease or other atherosclerotic disease, diabetes or hypertension. The donors
denied the history of smoking, alcohol consumption, or drug use
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using genomic DNA extracted from tails. These mice
were kept under standard animal room conditions
(temperature 21 ± 1°C; humidity 55–60%) with food
and water continuously available for one week before
the experiment.
Animal model of carotid atherosclerosis
All ApoE−/− mice mice (male, 8 weeks old) received
a high-fat diet (0.5% cholesterol and 15% cocoa but-
ter) until sacrifice. After four weeks of high-fat diet, a
silica-gel constrictive collar (0.30 mm inner diameter,
0.50 mm outer diameter, and 2 mm long) was placed
around right carotid artery in all mice as described
[28]. Three days after surgery, 200 μl of PBS (Phos-
phate Buffered Saline), 200 μl of native HDL, Cl-
HDL, or NO2-HDL at an apoA-I concentration of
500 μg/ml was injected via the tail vein every three
days for 4 weeks. The mice were euthanized by over-
dose of anesthetics at the end of experiment.
Plaque Morphology & Histochemical Analysis
Atherosclerotic plaques at the aortic valve level were
sectioned. Plaque morphological characters were ana-
lyzed via hematoxylin/eosin (H&E) staining. Plaque
composition was detected by oil red O staining (lipid-
rich cores), Sirius staining (collagen), Masson staining
(fibrin), anti–α smooth muscle actin antibody (smooth
muscle cells) staining, and anti–CD68 antibodies (mac-
rophages) staining. Slides were visualized under a bright-
field microscope (Leica DM2500, Tokyo, Japan), and
pictures of the entire slice were taken with identical
exposure settings for all sections and analyzed using
image analysis software (ImageJ, National Institutes of
Health, Bethesda, MD, USA). The abundance of each
component was evaluated as percent of the vascular
intima area. The vulnerable index was calculated as fol-
lows: the relative positive staining areas of (macro-
phages% + lipid%)/the relative positive staining areas of
(SMCs% + collagen%) [29].
Statistical analysis
All experiments were performed in triplicate unless indi-
cated. The results of multiple observations are presented
as the means ± SEM or as a representative result. Data
were analyzed with SPSS version 19.0 (IBM SPSS,
Armonk, NY, USA). Kolmogorov-Smirnov test was
employed to analyze native distribution, independent
sample t-tests was used to compare the difference be-
tween groups, difference was considered significant
when p < 0.05.
Other materials and methods please refer to Add-
itional file 1.
Results
MPO oxidation results in Cl-oxHDL and NO2-oxHDL
We have found previously through Mass Spectrom-
etry that major protein component of HDL, apoA-I,
is specifically modified upon MPO-catalyzed nitra-
tion and chlorination [26]. We showed that the
tyrosine (Y) chlorination and nitration events were
identified only in the MPO-treated samples. The chlori-
nated Y peptide was identified only in Cl-HDL and the
nitrated Y peptides were identified only in NO2-HDL
samples [26], which proved the specificity of our method.
Importantly, it was found recently that a 2-oxindolyl ala-
nine (2-OH-Trp) moiety at Tryptophan (W) 72 of apoA1
is critical in MPO-mediated inhibition of the ATP-binding
cassette transporter A1 (ABCA1)-dependent cholesterol
acceptor activity of apoA1 in vitro and in vivo [9]. ApoA1
containing a 2-OH-W72 group is abundant in
atherosclerosis-laden arteries and could predict CHD risk
[9]. Here we found that MPO-catalyzed nitration and
chlorination also results in the oxidation of W72 to form
Fig. 1 Mass Spectrometry analysis of HDL and MPO oxidized HDL.
a Results from the selected ion monitoring (SIM) analysis of the
native HDL, Cl-HDL and NO2-HDL samples. The data were obtained
by normalizing the peak areas for the W72 containing peptides
(LLDNWDSVTSTFSK) by the peak areas of the reference peptides.
The reference peptides utilized in these experiments are the
unmodified apoA-I peptides ATEHLSTLSEK and QGLLPVLESFK.
b Oxidized W72 of the native HDL, Cl-HDL and NO2-HDL samples
was also analyzed, with singly oxidized product, W + O (16 Da),
doubly oxidized product, W + 2O (32 Da), and the oxidation of W
to kynurenine (W + 4 Da) (**p < 0.01 compared with HDL group)
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the singly oxidized product, W +O (16 Da), doubly oxi-
dized product, W + 2O (32 Da), and the oxidation of W to
kynurenine [30] (W+ 4 Da) (Fig. 1). These findings
reflected the pathophysiological importance of the MPO
oxidized HDL in our experiments.
Cl-oxHDL and NO2-oxHDL have reduced capacity to
stimulate SMC proliferation
In order to examine the effects of Cl-oxHDL and
NO2-oxHDL on SMC proliferation, we employed
MTT and BrdU assays. We found that after 48 h
treatment with 100 μg /ml native HDL, cell number
increased by about 50% compared with non-treated
cells as indicated by the MTT assay (Fig. 2a). To ex-
clude the effect of MPO on cell proliferation, we
also set up MPO + HDL group in the MTT assay,
but the results showed no significant difference be-
tween MPO + HDL and HDL groups. However, Cl-
oxHDL and NO2-oxHDL had significantly dimin-
ished stimulatory effects on cell proliferation com-
pared with native HDL (Fig. 2a), with their MTT
values 33% and 24% higher than the non-treated
group, respectively. As shown in Fig. 2b, BrdU assay
showed similar results. DNA synthesis was stimu-
lated by about 60% in cells treated with HDL or
HDL +MPO compared with cells in non-treated
group. Cl-oxHDL and NO2-oxHDL groups were
associated with reduced stimulation of DNA synthe-
sis compared with native HDL (p < 0.01), but still
stimulated DNA synthesis by 35% and 29%, respect-
ively, compared with non-treated group. Results in
Additional file 1: Figure S1B revealed that the stimu-
latory effects on BrdU incorporation were time-
dependent.
Cl-oxHDL and NO2-oxHDL inhibited SMC migration
We first used in vitro wound healing assay to exam-
ine Cl-oxHDL and NO2-oxHDL’s effects on SMC mi-
gration. We found that HDL increased the migration
of SMCs by 70% compared with non-treated cells.
However, Cl-oxHDL and NO2-oxHDL inhibited SMC
migration by about 54% and 58%, respectively, com-
pared with non-treated cells (Fig. 3a and c). We also
used transwell assay to confirm these findings. As
shown in Fig. 3b and d, HDL increased SMCs migra-
tion by about 50% compared with non-treated cells,
while Cl-oxHDL and NO2-oxHDL inhibited SMC mi-
gration by about 60% and 50%, respectively, compared
with non-treated cells. Data in Additional file 1:
Figure S1A confirmed that the transwell migration
was in dose-dependent manner. These results clearly
showed that HDL of healthy subjects promotes the
migration of SMCs, while MPO catalyzed oxHDL in-
hibits SMC migration.
Cl-oxHDL and NO2-oxHDL had no significant effects on
SMC apoptosis
We used Annexin-V apoptosis assay to examine Cl-
oxHDL and NO2-oxHDL’s effects on SMC apoptosis.
We found that 24 h treatment with either 100 μg /ml
native or oxHDL did not significantly affect SMC apop-
tosis (Additional file 1: Figure S2).
Fig. 2 oxHDL reduces HDL’s promotion of SMC proliferation. a In
vitro MTT assay was performed to analyze SMC viability. The native
HDL and oxHDL was applied to SMCs at a concentration of 100 μg/ml
for 48 h. The absorbance at A570 was measured and compared. b In
vitro BrdU assay was performed to analyze SMC proliferation. The native
HDL and oxHDL were applied to SMCs at a concentration of 100 μg /ml
for 48 h. The absorbance at A450 was measured and compared
(*p < 0.05, **p < 0.01 compared with non-treated group (NT), ##p
< 0.01 compared with HDL group)
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Cl-oxHDL and NO2-oxHDL have diminished capacity to
activate ERK1/2 phosphorylation
The mitogen-activated protein kinase (MAPK)/ extra-
cellular regulated protein kinases (ERK) pathways
have been proved to play a vital role in modulating
SMC migration and proliferation [25, 31]. The phos-
phorylation state of ERK1/2 is the marker for activa-
tion of MAPK/ERK pathway [32]. To further
elucidate the mechanism by which Cl-oxHDL and
NO2-oxHDL inhibit SMC migration, we determined
whether ERK1/2 phosphorylation was affected. SMCs
were treated with native HDL, Cl-oxHDL and NO2-
oxHDL at an apoA-I concentration of 100 μg/ml for
5, 15, and 30 min. In Fig. 4a and b, our results
showed that ERK1/2 phosphorylation in the three
groups reached maximum at the same time point
(5 min) and treatment with native HDL significantly
increased the level of ERK1/2 phosphorylation by
about 150%. However, Cl-oxHDL and NO2-oxHDL
had dramatic reduction in stimulating phosphorylation
of ERK1/2 compared with native HDL. Cl-oxHDL
and NO2-oxHDL treatment for 5 min resulted in
about 60% and 20% reduction of ERK1/2 phosphoryl-
ation, respectively, compared with HDL group. These
results illustrate that Cl-oxHDL and NO2-oxHDL
have diminished capacity to activate ERK1/2 as indi-
cated by their phosphorylation.
Cl-oxHDL and NO2-oxHDL inhibit SMC migration through
the MAPK pathway
To test whether Cl-oxHDL and NO2-oxHDL inhibit
SMC migration through MAPK pathway, we pre-
treated SMCs with LY294002 (a PI3K inhibitor) and
PD98059 (a MAPK inhibitor), and repeated the
transwell assay. As shown in Fig. 5, PD98059 treat-
ment abolished the differences of SMC migration re-
sponses between HDL, Cl-oxHDL and NO2-oxHDL
groups, while LY294002 failed to do so. These results
Fig. 3 Oxidation of HDL inhibits SMC migration while HDL promotes SMC migration. a Primary aortic SMCs were cultured on 12-well plate
until confluent, when an in vitro wound healing assay was performed. The native HDL and oxHDL were applied to SMCs at a concentration of
100 μg /ml for 48 h. Photographs of cells were taken 48 h after scratch. b In vitro transwell assay was performed to analyze SMC migration.
The native and oxHDL were applied to SMCs at a concentration of 100 μg /ml for 12 h. The cells were stained and photographed. c The cells i
n wound healing assay were photographed 0 and 48 h after scratch, the relative area of SMC migration was compared. d Migrated cells in
transwell assay were counted and compared (*p < 0.05, **p < 0.01 compared with non-treated group (NT), ##p < 0.01 compared with HDL group)
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suggested that Cl-oxHDL and NO2-oxHDL inhibit
SMC migration through MAPK but not PI3K/Akt
pathway.
HDL, Cl-oxHDL and NO2-oxHDL’s effects on SMC
migration are dependent on SR-BI
HDL’s cholesterol transport function needs binding
with its receptor Scavenger Receptor Class B Type I
(SR-BI) [33]. It was reported recently that in endothe-
lial cells and breast cancer cells, HDL modulates
proliferation and migration through SR-BI [27, 34].
We reported previously oxidized HDL can inhibit SR-
BI expression in endothelial cell [26]. However, it
remains unknown in SMCs, whether HDL modulates
migration through SR-BI. To determine whether
HDL, Cl-oxHDL and NO2-oxHDL’s effects on SMC
migration were dependent on SR-BI, we performed
transwell experiments using SMCs derived from SR-
BI (−/−) mice. Representative agarose gel of SR-BI
mouse genotype assay by PCR was shown in Fig. 6a.
The lack of SR-BI expression in the SR-BI (−/−)
SMCs was confirmed by western blot (Fig. 6b). As
seen in Fig. 6c and d, there was no significant differ-
ence among migration responses of SR-BI (−/−) SMCs
treated without (non-treated) and with native HDL or
oxHDL. These results indicated that native and
oxHDL’s effects on SMC migration may be dependent
on SR-BI.
Cl-oxHDL and NO2-oxHDL inhibit platelet-derived growth
factor (PDGF)-induced migration of SMCs
In atherosclerosis, PDGF-BB released from platelets,
monocytes and endothelial cells could significantly
promote SMC migration [35]. Reports have shown
that HDL could inhibit PDGF-BB-stimulated SMC
migration [36, 37]. Therefore, to answer whether Cl-
oxHDL and NO2-oxHDL could influence PDGF-BB-
stimulated SMC migration, we performed transwell
assay in the presence of 30 ng/ml PDGF-BB. As
shown in Additional file 1: Figure S3, native HDL
Fig. 4 HDL stimulates ERK pathway while oxHDL inhibits such
pathway. a The native and oxHDL were applied to SMCs at a
concentration of 100 μg /ml for 5, 15 and 30 min, before cells were
harvested for western blot. b The band density of phospha-ERK
(P-ERK), ERK was determined by Photoshop 7.0 software. The ratio of
pERK/ERK were compared. (**p < 0.01 compared with HDL group)
Fig. 5 PD98059, but not LY294002, reverses inhibitory effects of
oxHDL on SMC migraiton. a SMCs were preincubated with in the
presence or absence of LY294002 (50 μM) or PD98059 (10 μM) for
12 h. Then cells were treated with HDL for 5 min, cell lysates were
analyzed by western blot. b LY294002 and PD98059 were applied
12 h before transwell experiments were performed. The migrating
cells were stained and photographed after 12 h incubation. c The
number of migrated cells were counted and compared, normalized
to the number of migrated cells in non-treated HDL group
(**p < 0.01 compared with HDL groups in each treatments)
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significantly suppressed PDGF-BB stimulated SMC
migration, while Cl-oxHDL and NO2-oxHDL could
still significantly suppress SMC migration compared
with native HDL.
HDL, Cl-oxHDL and NO2-oxHDL’s effects on atherosclerotic
plaque stability
To determine the effects of HDL, Cl-oxHDL and NO2-
oxHDL’s on atherosclerotic plaque stability, we
performed coratid artery collar implantation in apoE−/−
mice on high-fat diet. Same amount of PBS, HDL,
Cl-oxHDL and NO2-oxHDL (200 μl, at the concentra-
tion of 500 μg/ml) was injected via tail vein every
three days after collar implantation. At 4 weeks after
collar implantation, we found increased neointima to
media ratio in Cl-oxHDL and NO2-oxHDL treated
groups compared with HDL group (p < 0.05, Figs. 7
and 8a). Moreover, significantly less SMC positive
staining cells and significantly more CD68 positive
staining cells were present in Cl-oxHDL and NO2-
oxHDL treated groups compared with HDL group (p
< 0.05, Figs. 7 and 8b), while no significant difference
of collagen, fibrin and lipids staining was noticed
between the four groups (Figs. 7 and 8b). We
calculated the vulnerable index as described [29], and
found significantly elevated relative vulnerable index
in Cl-oxHDL and NO2-oxHDL treated groups com-
pared with HDL group (p < 0.05, Fig. 8c).
Discussion
In the current study, we have examined whether
MPO-oxidized HDL (NO2- and Cl-oxHDL) modulates
SMC proliferation, migration and apoptosis. Our re-
sults have revealed: 1) NO2-oxHDL and Cl-oxHDL
inhibit SMC migration through the MAPK-ERK path-
way dependent of SR-BI, 2) NO2-oxHDL and Cl-
oxHDL inhibit PDGF-induced SMC migration, 3)
NO2-oxHDL and Cl-oxHDL have impaired capacity
to stimulate proliferation of SMCs, 4) NO2-oxHDL
and Cl-oxHDL did not increase apoptosis of SMCs,
and 5) NO2-oxHDL and Cl-oxHDL induced neoin-
tima formation and reduced SMC positive staining
cells in atherosclerotic plaque.
At the early stage of atherosclerotic development,
migration and proliferation of vascular SMCs play
critical roles in neointima formation [35]. At the late
stage, apoptosis of SMCs reduces plaque stability in
atherosclerotic lesions, but migration and proliferation
Fig. 6 Native and oxHDL’s effects on SMC migration are dependent on SR-BI. a Representative agarose gel of SR-BI genotype assay by PCR. Wild
type (WT) mice were identified by a band at 630 bp, while SR-BI (−/−) mice were identified by band at 330 bp. b Western blot analysis of SMCs
from wild type (WT) and SR-BI (−/−) mice. c In vitro transwell assay was performed to analyze aortic SMC migration in SR-BI (−/−) mice.
The native and oxHDL was applied to SMC at a concentration of 100 μg /ml for 12 h. The cells were stained and photographed. d Migrating cells were
counted and compared (no significant difference was observed between the four groups)
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of SMCs enhance stability of atherosclerotic plaque
[21–23]. HDL, a well-accepted cardioprotective factor,
was reported to promote SMC proliferation [24, 25, 38],
likely contributing to its cardioprotection [1, 39]. Notably,
previous studies have clearly demonstrated a positive cor-
relation between serum MPO and acute coronary syn-
drome in patients [17, 18], strongly suggesting a role of
MPO in instability of atherosclerotic plaque. Although
our results showed that MPO-oxidized HDL did not in-
crease apoptosis, we have demonstrated that both NO2-
oxHDL and Cl-oxHDL oxidized by MPO significantly in-
hibit SMC migration and lose their capacity to stimulate
SMC proliferation compared with native HDL. It remains
unaddressed here whether MPO-oxidized HDL inhibits
proliferation of SMCs induced by other mitogens. How-
ever, we have demonstrated that HDL inhibits PDGF-
induced migration of vascular SMCs, which is consistent
with previous studies [36, 37]. Notably, MPO-oxidized
HDLs are even more potently in inhibition of PDGF-
induced migration of SMCs.
In an animal model of carotid atherosclerosis, we
found NO2-oxHDL and Cl-oxHDL induced neointima
formation while reduced SMC positive staining cells in
atherosclerotic plaque, resulting in elevated vulnerable
index of atherosclerotic plaque. Previous studies showed
injection of recombinant apoA1 could reduce plaque
burden [40, 41]. While in our experiments, we used na-
tive human HDL injection in a collar implantation
model, which may explain the differences of results.
Taken together, our data have provided at least partial
explanation to the mechanism underlying MPO-related
plaque instability [11–14].
Fig. 7 Native and oxHDL’s effects on plaque stability. a Representative images of H&E staining; b Representative images of Sirius red staining;
c Representative images of Masson staining; d Representative images of immunostaining for CD68; e Representative images of immunostaining
for α-SMC actin; f Representative images of Oil Red O staining (n = 6 in each group, scale bar = 50 μm)
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Although we have not studied further why MPO-
oxidized HDLs have impaired capacity to stimulate prolif-
eration of SMCs compared with native HDL, we have in-
vestigated the signaling mechanisms underlying inhibition
of SMC migration by oxHDLs. Our results have shown
that HDL stimulates migration of SMCs, to our surprise,
MPO-oxidized HDL even reduced the basal level of mi-
gration activities. It appears that either HDL-induced
stimulation or oxHDL-induced inhibition of migration of
SMCs requires the presence of SR-BI, because neither
HDL nor NO2-oxHDL and Cl-oxHDL induced any
changes in migration responses in SMCs derived from SR-
BI (−/−) mice. Whether NO2-oxHDL and Cl-oxHDL can
inhibit SR-BI expression or MPO-oxidized HDL lower the
binding between HDL and SR-BI needs further study. The
opposite effects on migration response by HDL and NO2-
oxHDL and Cl-oxHDL may result from differential effects
on the MAPK pathway. First, previous studies have shown
that activation of the MAPK pathway plays a critical role
in migration of vascular SMCs. Indeed, treatment with
PD98059 significantly inhibited HDL-induced migration
responses. Second, NO2-oxHDL and Cl-oxHDL induced
only a transient activation of MAPK. In response to treat-
ment with NO2-oxHDL, phosphorylation of MAPK re-
duced to the basal level at 5 min, which were almost
undetectable at 15 min. In response to treatment with Cl-
oxHDL, the phosphorylation level of MAPK at 5 min was
much lower than the basal level. Finally, PD98059 treat-
ment could reverse the inhibition of migration response of
SMCs induced by both NO2-oxHDL and Cl-oxHDL.
Fig. 8 Native and oxHDL’s effects on plaque morphology & stability. a Statistical results of neointima/media ratio; b Statistical results of relative
abundances (The abundance of each component was evaluated as percent of the vascular intima area) of SMA, collagen, fibrin, CD68 and lipids;
c. Statistical results of plaque vulnerable index (values are mean ± SEM, *p < 0.05 compared with HDL group)
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Given that MPO is a hallmark of unstable atheroscler-
otic plaque and acute coronary events [11–14] and re-
cent reports show that HDL is associated with MPO in
ACS patients [17–19], our findings demonstrating that
MPO-catalyzed HDL nitration and chlorination regulate
SMC proliferation and migration have proposed a
novel hypothesis on MPO’s role in plaque stability
(Fig. 9). In atherosclerotic plaque, HDL was oxidized
by MPO released from macrophages and generated
Cl-oxHDL and NO2-oxHDL, which inhibited SMC
migration and proliferation, resulting in reduced SMC
population in the fibrous cap, which may ultimately
lead to plaque instability.
Conclusion
Our findings implicate MPO-catalyzed oxidization of
HDL may contribute to atherosclerotic plaque instability
by inhibiting SMC proliferation and migration through
MAPK-ERK pathway which was dependant on SR-BI,
which may surve as potential therapeutic target in ACS.
Additional file
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(DOC 125 kb)
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Fig. 9 Cartoon of a hypothesis on MPO’s role in plaque stability. SMC = smooth muscle cell; EC = endothelial cell; Mφ =macrophage; HDL = high
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